Rhodiola rosea 'WS 1375'

Rhodiola rosea 'WS 1375' is a standardized proprietary dry extract of Rhodiola rosea root, not a conventional food ingredient, so macronutrient and micronutrient framing is largely inapplicable; its profile is defined by its bioactive phytochemical fingerprint. The extract is standardized to contain rosavins (rosavin, rosarin, rosin) at approximately 3% total content and salidroside (p-tyrosol glucoside) at approximately 1% — a 3:1 rosavin-to-salidroside ratio reflecting the natural root composition and used as a quality marker. Typical clinical doses of WS 1375 are 200–400 mg/day of the dry extract. Key bioactive compound classes include: (1) Phenylpropanoids — rosavins (~3% standardized), the glycosylated cinnamyl alcohol derivatives considered primary marker compounds; (2) Phenylethanoids — salidroside (~1% standardized), also known as rhodioloside, a tyrosine-derived glucoside with well-documented adaptogenic and neuroprotective activity; its aglycone p-tyrosol is also present in smaller amounts and contributes to bioactivity; (3) Flavonoids — including rodiolin, rodionin, rodiosin, acetylrodalgin, and tricin, present at trace-to-low percentages; (4) Monoterpene alcohols — geraniol and myrtenol detected in volatile fractions; (5) Organic acids — gallic acid, chlorogenic acid, and hydroxycinnamic acid derivatives present at low milligram-per-gram levels; (6) Proanthocyanidins — oligomeric forms present in root matrix. Macronutrient content at clinical doses is negligible: at 200–400 mg extract per dose, carbohydrate, fat, and protein contributions are physiologically insignificant (estimated <0.1 g each per dose). Mineral content from the extract at these doses is trace-level and not a meaningful dietary source. Bioavailability notes: salidroside is hydrolyzed in the gastrointestinal tract to p-tyrosol, which is rapidly absorbed; peak plasma concentrations of p-tyrosol are reached within approximately 1 hour post-ingestion. Rosavins undergo partial hydrolysis and phase II conjugation (glucuronidation, sulfation) in intestinal and hepatic metabolism; absolute oral bioavailability data for intact rosavins in humans remains limited, though animal studies suggest moderate absorption with first-pass metabolism reducing systemic exposure. The extract matrix (dry powder from hydroethanolic extraction) does not contribute meaningful dietary fiber, fat-soluble vitamins, or minerals at therapeutic doses.